PROM1 and central nervous system cancer: In a clinical study targeting three glioblastoma patients treated by intracranial adoptive transfer of autologous IL-13Rα2-specific CTL clones, safe antiglioma responses against antigen positive CD133+glioma stem cells as well as antigen positive glioma cells were documented, but IL-13Rα2 antigen was not expressed in the eventually recurred tumor [165].